TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04085692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Dose, High-Frequency Simulation-Based Training
Description: Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback
Study: NCT03186872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital behavioral program app
Description: mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
Study: NCT01186094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: Sirolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor Resolute
Description: Zotarolimus-eluting Stent
Study: NCT00666380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Malaria Protein 010 (FMP010)
Description: Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Malaria Protein 010 (FMP010)
Description: Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
Study: NCT04260529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyPep-1
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [KEYTRUDA®]
Description: IV infusion
Study: NCT05145686

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Matris metalloproteinase -2, -8, -9 expressions
Description: . The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Matris metalloproteinase -2, -8, -9 expressions
Description: . The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
Study: NCT00598104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03283761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m^2
Description: Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m^2
Description: Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU 1200 mg/m^2 x 2 D
Description: Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin 400 mg/m^2
Description: Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Study: NCT01573169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
Description: placebo standard therapy
Study: NCT03554213

Intervention type: BIOLOGICAL
Intervention: Typhoid Conjugate Vaccine
Description: Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited

Intervention type: BIOLOGICAL
Intervention: Typhoid Conjugate Vaccine
Description: Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
Study: NCT02472028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood pressure lowering algorithm
Description: The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual strategy
Description: The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
Study: NCT01777620

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
Study: NCT03730571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AbsorbaSeal 6Fr Vascular Closure Device
Description: Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
Study: NCT02710474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
Study: NCT01167257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome encapsulated botulinum toxin A
Description: Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline instillation
Description: Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
Study: NCT02768714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurofarma's pegfilgrastim
Description: Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulastim
Description: Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
Study: NCT02216513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desferrioxamine (DFO)
Description: DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline IV for 4 hours for 5 consecutive days
Study: NCT00922519

Intervention type: OTHER
Intervention: 18F-Sodium Fluoride (Na18F)
Description: 200-400 MBq/injection, up to 6 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
Study: NCT02152982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04377555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
Study: NCT03683251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm
Study: NCT01421173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting dose: 200 mg by mouth on Days -8 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on Days -3 and -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Infusion of stem cells by vein on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: 8 mg by vein twice a day from day -8 AM to day -2 PM.
Study: NCT01905748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Description: Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
Study: NCT00525551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: 150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl)
Description: 300 mL 0.9% NaCl
Study: NCT03825341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea Oral Capsule
Description: Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
Study: NCT01455506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus Fludarabine and Busulfan
Description: * Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient \>20% above ideal body weight~* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~* Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0.
Study: NCT01857271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo thoracotomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01025271

Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin
Description: one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
Study: NCT00767169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate
Description: Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
Study: NCT03683251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm
Study: NCT02748525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CCK
Description: CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
Study: NCT03683251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant with Ranibizumab 100 mg/mL
Description: Will be administered as per the schedule described in individual arm
Study: NCT02941757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet Intervention
Description: 1. Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~2. Peer-education and support~3. Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~4. Email or text message encouragement and reminders during the intervention.
Study: NCT01312571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (iCBT)
Description: The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based computerized attention training
Description: The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
Study: NCT01987037

Intervention type: BEHAVIORAL
Intervention: neuropsychomotor assessment
Description: Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
Study: NCT05892692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ecological Momentary Intervention
Description: Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
Study: NCT02710474

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.
Study: NCT03554785

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician and Non-clinician staff training
Description: An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients.
Study: NCT03029767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise .
Description: The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
Study: NCT02710474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.
Study: NCT03029767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise
Description: The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.